The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

@article{Hartwell2014TheCE,
  title={The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.},
  author={Debbie Hartwell and Keith Cooper and Geoff K. Frampton and Louise Baxter and Emma Loveman},
  journal={Health technology assessment},
  year={2014},
  volume={18 65},
  pages={i-xxii, 1-202}
}
BACKGROUND Optimal therapy for children with chronic hepatitis C is unclear. Two treatment regimens are currently licensed in children. OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of peginterferon alfa-2a (Pegasys®, Roche) and peginterferon alfa-2b [ViraferonPeg®, Merck Sharp & Dohme (MSD)] in combination with ribavirin (RBV), within their licensed indications, for the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3-17 years. DATA… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 130 references

Costs and quality of life in patients with chronic hepatic diseases: The COME study results

  • S Abstract Fagiuoli, L Scalone, R Ciampichini, F Fusco, L Gaeta, PA Del
  • Digest Liver Dis 2012;56:S11
  • 2012

Costs and quality of life in patients with liver transplantation

  • S Abstract Fagiuoli, L Scalone, R Ciampichini, F Fusco, L Gaeta, PA Del
  • Liver Transplant 2012;18:S262
  • 2012

High rate of virological response to peginterferon alpha-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis

  • MA Moghaddam, MR Zali, SHA Andabili, F Derakhshan, SM Miri, SM. Alavian
  • C. Iranian Red Crescent Med J
  • 2012

Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C in Children and Young People Aged 3–17 Years: Manufacturer Submission of Evidence

  • Merck Sharp, Dohme Limited
  • 2012

Similar Papers

Loading similar papers…